首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1387146

多克隆抗體市場報告：2030 年趨勢、預測和競爭分析

Polyclonal Antibodie Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日期: 2023年10月27日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

多克隆抗體的趨勢與預測

預計到 2030 年，全球多株抗體市場將達到 68 億美元，2024 年至 2030 年年複合成長率為 7.8%。該市場的主要促進因素包括癌症和感染疾病患者的增加、生物製藥業務研發力度的增加以及抗體藥物技術開發的進步。全球多株抗體市場的未來前景廣闊，學術研究中心、製藥和生物技術公司、診斷中心和醫院市場存在商機。

多克隆抗體市場洞察

Lucintel 預測診斷學將在預測期內實現最高成長，因為多克隆抗體生產成本低廉且可在許多物種中獲得。

隨著越來越多的公司將多克隆抗體用於各種目的，包括藥物、診斷分析和研究工具，預計製藥和生物技術公司仍將是該市場中最大的部分。

由於生物技術和製藥行業的研發資金增加，以及該地區完善的醫院、診所和實驗室醫療保健系統，北美在預測期內仍然是最大的地區，並且仍將是區域性的。

本報告回答了 11 個關鍵問題：

Q.1. 細分市場中最有前途和高成長的機會是什麼？
Q.2.哪個細分市場將以更快的速度成長？為什麼？
Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
Q.5. 這個市場的商業風險和競爭威脅是什麼？
Q.6.這個市場有哪些新趨勢？為什麼？
Q.7.市場客戶需求有何改變？
Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

宏觀經濟趨勢（2018-2023）與預測（2024-2030）
全球多株抗體市場趨勢（2018-2023）與預測（2024-2030）
全球多克隆抗體市場（按產品）
- 一次
- 中學
按來源分類的全球多克隆抗體市場
- 兔子
- 山羊
- 羊
- 其他
全球多克隆抗體市場（按應用）
- 研究
- 診斷
- 治療
按最終用途分類的全球多克隆抗體市場
- 學術研究中心
- 製藥和生物技術公司
- 診斷中心
- 醫院

第4章 2018-2030年分地區市場趨勢及預測分析

全球多株抗體市場區域分佈
北美多株抗體市場
歐洲多株抗體市場
亞太多克隆抗體市場
其他地區多株抗體市場

第5章競爭分析

產品系列分析
營運整合
波特五力分析

第6章成長機會與策略分析

成長機會分析
- 全球多克隆抗體市場成長機會（按產品）
- 全球多克隆抗體市場成長機會（按來源）
- 全球多克隆抗體市場成長機會（按應用）
- 全球多克隆抗體市場成長機會（依最終用途）
- 全球多克隆抗體市場成長機會（按地區）
全球多克隆抗體市場的新趨勢
戰略分析
- 新產品開發
- 全球多株抗體市場產能擴張
- 全球多克隆抗體市場的合併、收購和合資企業
- 認證和許可

第7章主要企業概況

Thermo Fisher Scientific
Merck Abcam
Bio-Rad Laboratories
F. Hoffmann-La Roche
Cell Signaling Technology
Becton and Dickinson
PerkinElmer
GenScript
ioLegend
Creative Diagnostics

簡介目錄

Polyclonal Antibodie Trends and Forecast

The future of the global polyclonal antibodie market looks promising with opportunities in the academic & research center, pharmaceutical & biotechnology company, diagnostic center, and hospital markets. The global polyclonal antibodie market is expected to reach an estimated $6.8 billion by 2030 with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are rising cancer cases and infectious diseases, increasing R&D efforts in the biopharmaceutical business, and as well as the increasing technological developments in antibody-based medications.

A more than 150-page report is developed to help in your business decisions.

Polyclonal Antibodie by Segment

The study includes a forecast for the global polyclonal antibodie by product, source, application, end use, and region.

Polyclonal Antibodie Market by Product [Shipment Analysis by Value from 2018 to 2030]:

Primary
Secondary

Polyclonal Antibodie Market by Source [Shipment Analysis by Value from 2018 to 2030]:

Rabbits
Goats
Sheep
Others

Polyclonal Antibodie Market by Application [Shipment Analysis by Value from 2018 to 2030]:

Research
Diagnostics
Therapy

Polyclonal Antibodie Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

Academic & Research Center
Pharmaceutical & Biotechnology Companies
Diagnostic Centers
Hospitals

Polyclonal Antibodie Market by Region [Shipment Analysis by Value from 2018 to 2030]:

North America
Europe
Asia Pacific
The Rest of the World

List of Polyclonal Antibodie Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies polyclonal antibodie companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the polyclonal antibodie companies profiled in this report include-

Thermo Fisher Scientific
Merck Abcam
Bio-Rad Laboratories
F. Hoffmann-La Roche
Cell Signaling Technology
Becton And Dickinson
Perkinelmer
Genscript
Iolegend
Creative Diagnostics

Polyclonal Antibodie Market Insights

Lucintel forecasts that diagnostics is expected to witness highest growth over the forecast period as polyclonal antibody manufacturing is inexpensive to produce and the presence of numerous species in it.

Within this market, pharmaceutical and biotechnology companies is expected to remain the largest segment due to he increasing use ofpolyclonal antibodies by the pharmaceutical and biotechnology industries for a range of purposes, including medicines, diagnostic assays, and research tools.

North America will remain the largest region during the forecast period due to the growing funding for research and development in the biotechnology and pharamceutical industries and well-established healthcare system that comprises hospitals, clinics, and laboratories in the region.

Features of the Global Polyclonal Antibodie Market

Market Size Estimates: Polyclonal antibodie market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Polyclonal antibodie market size by various segments, such as by product, source, application, end use, and region in terms of value ($B).

Regional Analysis: Polyclonal antibodie market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products sources, applications, end uses, and regions for the polyclonal antibodie market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the polyclonal antibodie market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the polyclonal antibodie market size?

Answer: The global polyclonal antibodie market is expected to reach an estimated $6.8 billion by 2030.

Q2. What is the growth forecast for polyclonal antibodie market?

Answer: The global polyclonal antibodie market is expected to grow with a CAGR of 7.8% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the polyclonal antibodie market?

Answer: The major drivers for this market are rising cancer cases and infectious diseases, increasing R&D efforts in the biopharmaceutical business, and as well as the increasing technological developments in antibody-based medications.

Q4. What are the major segments for polyclonal antibodie market?

Answer: The future of the polyclonal antibodie market looks promising with opportunities in the academic & research center, pharmaceutical & biotechnology company, diagnostic center, and hospital markets.

Q5. Who are the key polyclonal antibodie market companies?

Answer: Some of the key polyclonal antibodie companies are as follows:

Thermo Fisher Scientific
Merck Abcam
Bio-Rad Laboratories
F. Hoffmann-La Roche
Cell Signaling Technology
Becton And Dickinson
Perkinelmer
Genscript
Iolegend
Creative Diagnostics

Q6. Which polyclonal antibodie market segment will be the largest in future?

Answer: Lucintel forecasts that diagnostics is expected to witness highest growth over the forecast period as polyclonal antibody manufacturing is inexpensive to produce and the presence of numerous species in it.

Q7. In polyclonal antibodie market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region during the forecast period due to the growing funding for research and development in the biotechnology and pharamceutical industries and well-established healthcare system that comprises hospitals, clinics, and laboratories in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the polyclonal antibodie market by product (primary and secondary), source (rabbits, goats, sheep, and others), application (research, diagnostics, and therapy), end use (academic & research center, pharmaceutical & biotechnology companies, diagnostic centers, and hospitals), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Global Polyclonal Antibodie Market : Market Dynamics

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Polyclonal Antibodie Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Polyclonal Antibodie Market by Product
- 3.3.1: Primary
- 3.3.2: Secondary
3.4: Global Polyclonal Antibodie Market by Source
- 3.4.1: Rabbits
- 3.4.2: Goats
- 3.4.3: Sheep
- 3.4.4: Others
3.5: Global Polyclonal Antibodie Market by Application
- 3.5.1: Research
- 3.5.2: Diagnostics
- 3.5.3: Therapy
3.6: Global Polyclonal Antibodie Market by End Use
- 3.6.1: Academic & Research Center
- 3.6.2: Pharmaceutical & Biotechnology Companies
- 3.6.3: Diagnostic Centers
- 3.6.4: Hospitals

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

4.1: Global Polyclonal Antibodie Market by Region
4.2: North American Polyclonal Antibodie Market
- 4.2.2: North American Polyclonal Antibodie Market by End Use: Academic & Research Center, Pharmaceutical & Biotechnology Companies, Diagnostic Centers, and Hospitals
4.3: European Polyclonal Antibodie Market
- 4.3.1: European Polyclonal Antibodie Market by Application: Research, Diagnostics, and Therapy
- 4.3.2: European Polyclonal Antibodie Market by End Use: Academic & Research Center, Pharmaceutical & Biotechnology Companies, Diagnostic Centers, and Hospitals
4.4: APAC Polyclonal Antibodie Market
- 4.4.1: APAC Polyclonal Antibodie Market by Application: Research, Diagnostics, and Therapy
- 4.4.2: APAC Polyclonal Antibodie Market by End Use: Academic & Research Center, Pharmaceutical & Biotechnology Companies, Diagnostic Centers, and Hospitals
4.5: ROW Polyclonal Antibodie Market
- 4.5.1: ROW Polyclonal Antibodie Market by Application: Research, Diagnostics, and Therapy
- 4.5.2: ROW Polyclonal Antibodie Market by End Use: Academic & Research Center, Pharmaceutical & Biotechnology Companies, Diagnostic Centers, and Hospitals

5. Competitor Analysis

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Polyclonal Antibodie Market by Product
- 6.1.2: Growth Opportunities for the Global Polyclonal Antibodie Market by Source
- 6.1.3: Growth Opportunities for the Global Polyclonal Antibodie Market by Application
- 6.1.4: Growth Opportunities for the Global Polyclonal Antibodie Market by End Use
- 6.1.5: Growth Opportunities for the Global Polyclonal Antibodie Market by Region
6.2: Emerging Trends in the Global Polyclonal Antibodie Market
6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Polyclonal Antibodie Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Polyclonal Antibodie Market
- 6.3.4: Certification and Licensing